Health Care & Life Sciences » Biotechnology | Neurocrine Biosciences Inc.

Neurocrine Biosciences Inc. | Ownership

Companies that own Neurocrine Biosciences Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Fidelity Management & Research Co.
11,983,999
13.25%
113,798
0.15%
06/30/2018
The Vanguard Group, Inc.
7,517,740
8.31%
259,443
0.03%
06/30/2018
Henderson Global Investors Ltd.
7,414,861
8.19%
-49,133
0.4%
06/30/2018
T. Rowe Price Associates, Inc.
5,930,307
6.56%
-334,357
0.1%
06/30/2018
Perceptive Advisors LLC
4,715,250
5.21%
-46,739
13.21%
06/30/2018
BlackRock Fund Advisors
4,480,204
4.95%
-52,405
0.03%
06/30/2018
Bellevue Asset Management AG
3,361,303
3.72%
-95,100
5.97%
06/30/2018
Wellington Management Co. LLP
2,405,500
2.66%
33,827
0.06%
06/30/2018
Invesco Advisers, Inc.
1,908,941
2.11%
-297,038
0.14%
06/30/2018
Artisan Partners LP
1,877,645
2.08%
-88,464
0.25%
06/30/2018

About Neurocrine Biosciences

View Profile
Address
12780 El Camino Real
San Diego California 92130
United States
Employees -
Website http://www.neurocrine.com
Updated 07/08/2019
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.